Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., Von Tresckow, J., Lange, E., Kiehl, M., Dreyling, M., Ritgen, M., Duerig, J., Tausch, E., Schneider, C., Stilgenbauer, S., Wendtner, C. M., Fischer, K., Goede, V, Hallek, M. and Eichhorst, B. . Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Full text not available from this repository.

Abstract

Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the GCLLSG. A total of 2975 pts with advanced CLL were reviewed for incidence of RT. Clinical, laboratory, and genetic data were pooled. Time-to-event data, starting from time of CLL diagnosis, of first-line therapy or of RT diagnosis, were analyzed by Kaplan-Meier methodology. One hundred and three pts developed RT (3%): 95 pts diffuse large B-cell lymphoma (92%) and eight pts Hodgkin lymphoma (8%). Median observation time was 53 months (interquartile range 38.1-69.5). Median OS from initial CLL diagnosis for pts without RT was 167 months vs 71 months for pts with RT (HR 2.64, CI 2.09-3.33). Median OS after diagnosis of RT was 9 months. Forty-seven pts (46%) received CHOP-like regimens for RT treatment. Three pts subsequently underwent allogeneic and two pts autologous stem cell transplantation. Our findings show that within a large cohort of GCLLSG trial participants, 3% of the pts developed RT after receiving first-line chemo- or chemoimmunotherapy. This dataset confirms the ongoing poor prognosis and high mortality associated with RT.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Al-Sawaf, O.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Robrecht, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bahlo, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fink, A. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cramer, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Von Tresckow, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lange, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kiehl, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dreyling, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ritgen, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Duerig, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tausch, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schneider, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stilgenbauer, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wendtner, C. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goede, VUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hallek, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eichhorst, B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-340743
DOI: 10.1038/s41375-020-0797-x
Journal or Publication Title: Leukemia
Publisher: NATURE PUBLISHING GROUP
Place of Publication: LONDON
ISSN: 1476-5551
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
B-CELL LYMPHOMA; PROGNOSTIC-FACTORS; 2ND MALIGNANCIES; HODGKIN LYMPHOMA; OPEN-LABEL; FLUDARABINE; CYCLOPHOSPHAMIDE; RITUXIMAB; THERAPY; CHEMOIMMUNOTHERAPYMultiple languages
Oncology; HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/34074

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item